STOCK TITAN

Tharimmune Announces Upcoming Conference Presentations

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Tharimmune (Nasdaq:THAR), a clinical-stage biotech company focused on inflammation and immunology therapeutics, announces participation in two upcoming conferences. Randy Milby, CEO, will attend the 2024 Spartan Capital Investor Conference on November 4, 2024, in New York, conducting one-on-one meetings. Additionally, Dr. Nir Barak, Chief Medical Advisor, will present new Phase 1 trial results for TH104 at the 75th AASLD Annual Conference on November 18, 2024, in San Diego. The presentation will focus on the correlation between TH104 pharmacokinetics and pruritus relief in cholestatic pruritus patients.

Tharimmune (Nasdaq:THAR), una azienda biotech in fase clinica focalizzata sulle terapie per l'infiammazione e l'immunologia, annuncia la partecipazione a due prossimi convegni. Randy Milby, CEO, parteciperà alla 2024 Spartan Capital Investor Conference il 4 novembre 2024 a New York, conducendo incontri uno-a-uno. Inoltre, Dr. Nir Barak, Chief Medical Advisor, presenterà i nuovi risultati della fase 1 della sperimentazione per TH104 alla 75a Conferenza Annuale AASLD il 18 novembre 2024 a San Diego. La presentazione si concentrerà sulla correlazione tra la farmacocinetica di TH104 e il sollievo dal prurito nei pazienti con prurito colestatico.

Tharimmune (Nasdaq:THAR), una empresa biotecnológica en etapa clínica centrada en terapias para la inflamación y la inmunología, anuncia su participación en dos próximas conferencias. Randy Milby, CEO, asistirá a la 2024 Spartan Capital Investor Conference el 4 de noviembre de 2024 en Nueva York, realizando reuniones uno a uno. Además, Dr. Nir Barak, Asesor Médico Principal, presentará nuevos resultados del ensayo de fase 1 para TH104 en la 75a Conferencia Anual de AASLD el 18 de noviembre de 2024 en San Diego. La presentación se enfocará en la correlación entre la farmacocinética de TH104 y el alivio del prurito en pacientes con prurito colestático.

Tharimmune (Nasdaq:THAR)는 염증 및 면역 치료에 초점을 맞춘 임상 단계의 생명공학 회사로, 두 개의 다가오는 컨퍼런스에 참여한다고 발표했습니다. Randy Milby CEO는 2024년 11월 4일 뉴욕에서 개최되는 2024 Spartan Capital Investor Conference에 참석하여 일대일 미팅을 진행할 것입니다. 또한, Dr. Nir Barak, 최고 의학 고문은 2024년 11월 18일 샌디에고에서 열리는 제75회 AASLD 연례 회의에서 TH104의 새로운 1상 시험 결과를 발표할 예정입니다. 이 발표는 TH104의 약리학적 작용과 담즙정체성 가려움증 환자에서의 가려움증 완화 간의 상관관계에 초점을 맞출 것입니다.

Tharimmune (Nasdaq:THAR), une entreprise biopharmaceutique en phase clinique axée sur les thérapies contre l'inflammation et l'immunologie, annonce sa participation à deux prochaines conférences. Randy Milby, CEO, assistera à la 2024 Spartan Capital Investor Conference le 4 novembre 2024 à New York, où il conduira des réunions individuelles. De plus, Dr. Nir Barak, Conseiller Médical Principal, présentera les nouveaux résultats de l'essai de phase 1 pour TH104 lors de la 75e Conférence Annuelle AASLD le 18 novembre 2024 à San Diego. La présentation se concentrera sur la corrélation entre la pharmacocinétique de TH104 et le soulagement du prurit chez les patients souffrant de prurit cholestatique.

Tharimmune (Nasdaq:THAR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien für Entzündungen und Immunologie konzentriert, gibt die Teilnahme an zwei bevorstehenden Konferenzen bekannt. Randy Milby, CEO, wird am 4. November 2024 an der 2024 Spartan Capital Investor Conference in New York teilnehmen und Einzelgespräche führen. Darüber hinaus wird Dr. Nir Barak, Chief Medical Advisor, am 18. November 2024 auf der 75. AASLD-Jahrestagung in San Diego neue Ergebnisse der Phase-1-Studie für TH104 präsentieren. Der Vortrag wird sich auf die Korrelation zwischen der Pharmakokinetik von TH104 und der Linderung von Juckreiz bei Patienten mit cholestatischem Juckreiz konzentrieren.

Positive
  • None.
Negative
  • None.

BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.

Randy Milby, Chief Executive Officer, will attend the 2024 Spartan Capital Investor Conference being held on November 4, 2024 in New York and hold one-on-one meetings. Interested investors can register to attend the conference and schedule meetings here.

Event: 2024 Spartan Capital Investor Conference

Date: Monday, November 4, 2024

Location: The Pierre Hotel, New York City

Nir Barak, M.D., Chief Medical Advisor, will present new results from the Company's Phase 1 trial of TH104 in a poster titled "Poster Number 4348: Correlation Between the Pharmacokinetics of TH104 and Pruritus Relief in Patients with Cholestatic Pruritus," at the 75th American Association for the Study of Liver Diseases (AASLD) Annual Conference at The Liver Meeting® 2024 being held November 15-18 in San Diego.

Event: AASLDThe Liver Meeting® 2024

Date: Monday, November 18, 2024

Time: 8:00 a.m. to5:00 p.m. Pacific Time

Session IV: Human Cholestatic and Autoimmune Liver Diseases

Location: San Diego Convention Center Poster/Exhibit Hall

About Tharimmune

Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

Contacts:

Tharimmune, Inc.
ir@tharimmune.com

Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614

SOURCE: Tharimmune, Inc.



View the original press release on accesswire.com

FAQ

What will Tharimmune (THAR) present at the AASLD Liver Meeting 2024?

Tharimmune will present Phase 1 trial results of TH104, focusing on the correlation between pharmacokinetics and pruritus relief in cholestatic pruritus patients, through Poster Number 4348 on November 18, 2024.

Which conferences will Tharimmune (THAR) attend in November 2024?

Tharimmune will attend the 2024 Spartan Capital Investor Conference in New York on November 4 and the 75th AASLD Annual Conference in San Diego on November 18, 2024.

What is the focus of Tharimmune's (THAR) TH104 Phase 1 trial presentation?

The presentation focuses on the correlation between TH104's pharmacokinetics and pruritus relief in patients with cholestatic pruritus, to be presented at the AASLD Annual Conference.

Where and when will Tharimmune (THAR) present at the Spartan Capital Investor Conference?

Tharimmune will present at The Pierre Hotel in New York City on Monday, November 4, 2024, where CEO Randy Milby will conduct one-on-one meetings with investors.

Tharimmune, Inc.

NASDAQ:THAR

THAR Rankings

THAR Latest News

THAR Stock Data

3.86M
1.46M
1.79%
1.63%
43.25%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRIDGEWATER